nodes	percent_of_prediction	percent_of_DWPC	metapath
Aclidinium—BCHE—breast cancer	0.639	1	CbGaD
Aclidinium—CHRM3—muscle of abdomen—breast cancer	0.00609	0.344	CbGeAlD
Aclidinium—CHRM5—epithelium—breast cancer	0.0013	0.0733	CbGeAlD
Aclidinium—CHRM5—skin of body—breast cancer	0.00123	0.0697	CbGeAlD
Aclidinium—Tiotropium—CYP2D6—breast cancer	0.00103	0.396	CrCbGaD
Aclidinium—Tiotropium—CYP3A4—breast cancer	0.00088	0.34	CrCbGaD
Aclidinium—BCHE—nipple—breast cancer	0.000879	0.0497	CbGeAlD
Aclidinium—Gastrointestinal disorder—Ixabepilone—breast cancer	0.000815	0.00362	CcSEcCtD
Aclidinium—Urinary tract disorder—Goserelin—breast cancer	0.000807	0.00359	CcSEcCtD
Aclidinium—Urethral disorder—Goserelin—breast cancer	0.000801	0.00356	CcSEcCtD
Aclidinium—Vomiting—Lapatinib—breast cancer	0.000796	0.00354	CcSEcCtD
Aclidinium—Diarrhoea—Fulvestrant—breast cancer	0.000788	0.0035	CcSEcCtD
Aclidinium—Headache—Lapatinib—breast cancer	0.000784	0.00349	CcSEcCtD
Aclidinium—Infestation—Thiotepa—breast cancer	0.000779	0.00346	CcSEcCtD
Aclidinium—Infestation NOS—Thiotepa—breast cancer	0.000779	0.00346	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Letrozole—breast cancer	0.000767	0.00341	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Anastrozole—breast cancer	0.000767	0.00341	CcSEcCtD
Aclidinium—Eye disorder—Goserelin—breast cancer	0.000764	0.0034	CcSEcCtD
Aclidinium—Mediastinal disorder—Melphalan—breast cancer	0.000755	0.00336	CcSEcCtD
Aclidinium—Nasopharyngitis—Fluorouracil—breast cancer	0.000747	0.00332	CcSEcCtD
Aclidinium—Vomiting—Fulvestrant—breast cancer	0.000732	0.00325	CcSEcCtD
Aclidinium—Cardiac failure—Paclitaxel—breast cancer	0.000729	0.00324	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Raloxifene—breast cancer	0.000728	0.00324	CcSEcCtD
Aclidinium—Vomiting—Toremifene—breast cancer	0.000722	0.00321	CcSEcCtD
Aclidinium—Headache—Fulvestrant—breast cancer	0.000721	0.00321	CcSEcCtD
Aclidinium—Headache—Toremifene—breast cancer	0.000712	0.00316	CcSEcCtD
Aclidinium—Urinary tract disorder—Thiotepa—breast cancer	0.00069	0.00307	CcSEcCtD
Aclidinium—Urethral disorder—Thiotepa—breast cancer	0.000685	0.00305	CcSEcCtD
Aclidinium—Trospium—CYP2D6—breast cancer	0.000684	0.264	CrCbGaD
Aclidinium—Diarrhoea—Exemestane—breast cancer	0.000684	0.00304	CcSEcCtD
Aclidinium—Dysphonia—Epirubicin—breast cancer	0.000681	0.00303	CcSEcCtD
Aclidinium—Infection—Chlorambucil—breast cancer	0.000679	0.00302	CcSEcCtD
Aclidinium—Diabetes mellitus—Capecitabine—breast cancer	0.000672	0.00298	CcSEcCtD
Aclidinium—Vision blurred—Goserelin—breast cancer	0.000671	0.00298	CcSEcCtD
Aclidinium—Mediastinal disorder—Vinorelbine—breast cancer	0.00066	0.00293	CcSEcCtD
Aclidinium—Eye disorder—Thiotepa—breast cancer	0.000653	0.0029	CcSEcCtD
Aclidinium—Cough—Tamoxifen—breast cancer	0.00065	0.00289	CcSEcCtD
Aclidinium—Diarrhoea—Ixabepilone—breast cancer	0.000646	0.00287	CcSEcCtD
Aclidinium—Infestation NOS—Fluorouracil—breast cancer	0.000644	0.00286	CcSEcCtD
Aclidinium—Infestation—Fluorouracil—breast cancer	0.000644	0.00286	CcSEcCtD
Aclidinium—Cough—Melphalan—breast cancer	0.000637	0.00283	CcSEcCtD
Aclidinium—Nasopharyngitis—Paclitaxel—breast cancer	0.000637	0.00283	CcSEcCtD
Aclidinium—Vomiting—Exemestane—breast cancer	0.000636	0.00283	CcSEcCtD
Aclidinium—Sinusitis—Mitoxantrone—breast cancer	0.000631	0.0028	CcSEcCtD
Aclidinium—Dysphonia—Doxorubicin—breast cancer	0.00063	0.0028	CcSEcCtD
Aclidinium—Mediastinal disorder—Thiotepa—breast cancer	0.00063	0.0028	CcSEcCtD
Aclidinium—Headache—Exemestane—breast cancer	0.000626	0.00278	CcSEcCtD
Aclidinium—Cough—Goserelin—breast cancer	0.000621	0.00276	CcSEcCtD
Aclidinium—Dry mouth—Tamoxifen—breast cancer	0.00062	0.00276	CcSEcCtD
Aclidinium—Cardiac failure—Docetaxel—breast cancer	0.000618	0.00275	CcSEcCtD
Aclidinium—Diarrhoea—Letrozole—breast cancer	0.000608	0.0027	CcSEcCtD
Aclidinium—Diarrhoea—Anastrozole—breast cancer	0.000608	0.0027	CcSEcCtD
Aclidinium—Rhinitis—Mitoxantrone—breast cancer	0.000605	0.00269	CcSEcCtD
Aclidinium—Rhinitis—Irinotecan—breast cancer	0.000605	0.00269	CcSEcCtD
Aclidinium—Sinusitis—Fluorouracil—breast cancer	0.000604	0.00269	CcSEcCtD
Aclidinium—Infection—Tamoxifen—breast cancer	0.000604	0.00268	CcSEcCtD
Aclidinium—CHRM1—female reproductive system—breast cancer	0.000602	0.034	CbGeAlD
Aclidinium—Vomiting—Ixabepilone—breast cancer	0.0006	0.00267	CcSEcCtD
Aclidinium—Cardiac failure—Capecitabine—breast cancer	0.000599	0.00266	CcSEcCtD
Aclidinium—Dry mouth—Goserelin—breast cancer	0.000592	0.00263	CcSEcCtD
Aclidinium—Infection—Melphalan—breast cancer	0.000591	0.00263	CcSEcCtD
Aclidinium—Headache—Ixabepilone—breast cancer	0.000591	0.00263	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Chlorambucil—breast cancer	0.00059	0.00262	CcSEcCtD
Aclidinium—Rhinitis—Gemcitabine—breast cancer	0.00059	0.00262	CcSEcCtD
Aclidinium—CHRM3—adipose tissue—breast cancer	0.000586	0.0331	CbGeAlD
Aclidinium—Osteoarthritis—Capecitabine—breast cancer	0.000584	0.0026	CcSEcCtD
Aclidinium—Tachycardia—Melphalan—breast cancer	0.000581	0.00258	CcSEcCtD
Aclidinium—Urinary tract disorder—Gemcitabine—breast cancer	0.000581	0.00258	CcSEcCtD
Aclidinium—Rhinitis—Fluorouracil—breast cancer	0.00058	0.00258	CcSEcCtD
Aclidinium—Diarrhoea—Raloxifene—breast cancer	0.000577	0.00256	CcSEcCtD
Aclidinium—Diarrhoea—Idarubicin—breast cancer	0.000577	0.00256	CcSEcCtD
Aclidinium—Infection—Goserelin—breast cancer	0.000577	0.00256	CcSEcCtD
Aclidinium—Urethral disorder—Gemcitabine—breast cancer	0.000577	0.00256	CcSEcCtD
Aclidinium—Vision blurred—Thiotepa—breast cancer	0.000574	0.00255	CcSEcCtD
Aclidinium—Nervous system disorder—Goserelin—breast cancer	0.00057	0.00253	CcSEcCtD
Aclidinium—Tachycardia—Goserelin—breast cancer	0.000567	0.00252	CcSEcCtD
Aclidinium—Vomiting—Letrozole—breast cancer	0.000565	0.00251	CcSEcCtD
Aclidinium—Vomiting—Anastrozole—breast cancer	0.000565	0.00251	CcSEcCtD
Aclidinium—BCHE—skin of body—breast cancer	0.000563	0.0318	CbGeAlD
Aclidinium—CHRM2—endocrine gland—breast cancer	0.000559	0.0316	CbGeAlD
Aclidinium—Headache—Anastrozole—breast cancer	0.000557	0.00247	CcSEcCtD
Aclidinium—Headache—Letrozole—breast cancer	0.000557	0.00247	CcSEcCtD
Aclidinium—Cough—Vinorelbine—breast cancer	0.000556	0.00247	CcSEcCtD
Aclidinium—Urinary retention—Capecitabine—breast cancer	0.000555	0.00247	CcSEcCtD
Aclidinium—Infestation—Paclitaxel—breast cancer	0.000549	0.00244	CcSEcCtD
Aclidinium—Infestation NOS—Paclitaxel—breast cancer	0.000549	0.00244	CcSEcCtD
Aclidinium—Mediastinal disorder—Irinotecan—breast cancer	0.000544	0.00242	CcSEcCtD
Aclidinium—Nasopharyngitis—Docetaxel—breast cancer	0.00054	0.0024	CcSEcCtD
Aclidinium—CHRM3—female reproductive system—breast cancer	0.000539	0.0304	CbGeAlD
Aclidinium—Vomiting—Idarubicin—breast cancer	0.000536	0.00238	CcSEcCtD
Aclidinium—Vomiting—Raloxifene—breast cancer	0.000536	0.00238	CcSEcCtD
Aclidinium—Cough—Thiotepa—breast cancer	0.000531	0.00236	CcSEcCtD
Aclidinium—BCHE—endometrium—breast cancer	0.000531	0.03	CbGeAlD
Aclidinium—Mediastinal disorder—Gemcitabine—breast cancer	0.00053	0.00236	CcSEcCtD
Aclidinium—Headache—Raloxifene—breast cancer	0.000528	0.00235	CcSEcCtD
Aclidinium—Headache—Idarubicin—breast cancer	0.000528	0.00235	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Tamoxifen—breast cancer	0.000525	0.00233	CcSEcCtD
Aclidinium—Nasopharyngitis—Capecitabine—breast cancer	0.000522	0.00232	CcSEcCtD
Aclidinium—Infection—Vinorelbine—breast cancer	0.000517	0.0023	CcSEcCtD
Aclidinium—Sinusitis—Paclitaxel—breast cancer	0.000515	0.00229	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Melphalan—breast cancer	0.000514	0.00228	CcSEcCtD
Aclidinium—Nervous system disorder—Vinorelbine—breast cancer	0.00051	0.00227	CcSEcCtD
Aclidinium—CHRM1—endocrine gland—breast cancer	0.000509	0.0288	CbGeAlD
Aclidinium—Tachycardia—Vinorelbine—breast cancer	0.000508	0.00226	CcSEcCtD
Aclidinium—Diabetes mellitus—Methotrexate—breast cancer	0.0005	0.00222	CcSEcCtD
Aclidinium—Vision blurred—Mitoxantrone—breast cancer	0.000495	0.0022	CcSEcCtD
Aclidinium—Rhinitis—Paclitaxel—breast cancer	0.000494	0.00219	CcSEcCtD
Aclidinium—Infection—Thiotepa—breast cancer	0.000493	0.00219	CcSEcCtD
Aclidinium—CHRM3—female gonad—breast cancer	0.00049	0.0277	CbGeAlD
Aclidinium—BCHE—uterus—breast cancer	0.000489	0.0276	CbGeAlD
Aclidinium—Nervous system disorder—Thiotepa—breast cancer	0.000487	0.00217	CcSEcCtD
Aclidinium—Urinary tract disorder—Paclitaxel—breast cancer	0.000486	0.00216	CcSEcCtD
Aclidinium—Tachycardia—Thiotepa—breast cancer	0.000485	0.00215	CcSEcCtD
Aclidinium—Urethral disorder—Paclitaxel—breast cancer	0.000483	0.00215	CcSEcCtD
Aclidinium—BCHE—pituitary gland—breast cancer	0.00048	0.0271	CbGeAlD
Aclidinium—BCHE—adipose tissue—breast cancer	0.000478	0.027	CbGeAlD
Aclidinium—Vision blurred—Fluorouracil—breast cancer	0.000474	0.00211	CcSEcCtD
Aclidinium—Diabetes mellitus—Epirubicin—breast cancer	0.000468	0.00208	CcSEcCtD
Aclidinium—Diarrhoea—Chlorambucil—breast cancer	0.000467	0.00208	CcSEcCtD
Aclidinium—Infestation NOS—Docetaxel—breast cancer	0.000465	0.00207	CcSEcCtD
Aclidinium—Infestation—Docetaxel—breast cancer	0.000465	0.00207	CcSEcCtD
Aclidinium—Eye disorder—Paclitaxel—breast cancer	0.00046	0.00205	CcSEcCtD
Aclidinium—Cough—Irinotecan—breast cancer	0.000459	0.00204	CcSEcCtD
Aclidinium—Cough—Mitoxantrone—breast cancer	0.000459	0.00204	CcSEcCtD
Aclidinium—CHRM3—endocrine gland—breast cancer	0.000456	0.0258	CbGeAlD
Aclidinium—Infestation—Capecitabine—breast cancer	0.00045	0.002	CcSEcCtD
Aclidinium—Infestation NOS—Capecitabine—breast cancer	0.00045	0.002	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Vinorelbine—breast cancer	0.000449	0.002	CcSEcCtD
Aclidinium—Cough—Gemcitabine—breast cancer	0.000447	0.00199	CcSEcCtD
Aclidinium—Mediastinal disorder—Paclitaxel—breast cancer	0.000444	0.00197	CcSEcCtD
Aclidinium—BCHE—female reproductive system—breast cancer	0.00044	0.0248	CbGeAlD
Aclidinium—Osteoarthritis—Methotrexate—breast cancer	0.000435	0.00193	CcSEcCtD
Aclidinium—Vomiting—Chlorambucil—breast cancer	0.000434	0.00193	CcSEcCtD
Aclidinium—Diabetes mellitus—Doxorubicin—breast cancer	0.000433	0.00192	CcSEcCtD
Aclidinium—BCHE—adrenal gland—breast cancer	0.000429	0.0242	CbGeAlD
Aclidinium—Gastrointestinal disorder—Thiotepa—breast cancer	0.000429	0.00191	CcSEcCtD
Aclidinium—Diarrhoea—Vinblastine—breast cancer	0.000428	0.0019	CcSEcCtD
Aclidinium—Infection—Irinotecan—breast cancer	0.000426	0.00189	CcSEcCtD
Aclidinium—Infection—Mitoxantrone—breast cancer	0.000426	0.00189	CcSEcCtD
Aclidinium—Nervous system disorder—Irinotecan—breast cancer	0.000421	0.00187	CcSEcCtD
Aclidinium—Tachycardia—Mitoxantrone—breast cancer	0.000419	0.00186	CcSEcCtD
Aclidinium—Rhinitis—Docetaxel—breast cancer	0.000418	0.00186	CcSEcCtD
Aclidinium—Cardiac failure—Epirubicin—breast cancer	0.000417	0.00185	CcSEcCtD
Aclidinium—Diarrhoea—Tamoxifen—breast cancer	0.000416	0.00185	CcSEcCtD
Aclidinium—Infection—Gemcitabine—breast cancer	0.000415	0.00185	CcSEcCtD
Aclidinium—BCHE—bone marrow—breast cancer	0.000415	0.0235	CbGeAlD
Aclidinium—Urinary tract disorder—Docetaxel—breast cancer	0.000412	0.00183	CcSEcCtD
Aclidinium—Nervous system disorder—Gemcitabine—breast cancer	0.00041	0.00182	CcSEcCtD
Aclidinium—Urethral disorder—Docetaxel—breast cancer	0.000409	0.00182	CcSEcCtD
Aclidinium—Infection—Fluorouracil—breast cancer	0.000408	0.00181	CcSEcCtD
Aclidinium—Diarrhoea—Melphalan—breast cancer	0.000407	0.00181	CcSEcCtD
Aclidinium—Osteoarthritis—Epirubicin—breast cancer	0.000407	0.00181	CcSEcCtD
Aclidinium—Rhinitis—Capecitabine—breast cancer	0.000405	0.0018	CcSEcCtD
Aclidinium—Vision blurred—Paclitaxel—breast cancer	0.000404	0.0018	CcSEcCtD
Aclidinium—Nervous system disorder—Fluorouracil—breast cancer	0.000403	0.00179	CcSEcCtD
Aclidinium—Tachycardia—Fluorouracil—breast cancer	0.000401	0.00178	CcSEcCtD
Aclidinium—Urinary tract disorder—Capecitabine—breast cancer	0.000399	0.00177	CcSEcCtD
Aclidinium—Vomiting—Vinblastine—breast cancer	0.000398	0.00177	CcSEcCtD
Aclidinium—Diarrhoea—Goserelin—breast cancer	0.000397	0.00177	CcSEcCtD
Aclidinium—Urethral disorder—Capecitabine—breast cancer	0.000396	0.00176	CcSEcCtD
Aclidinium—Headache—Vinblastine—breast cancer	0.000392	0.00174	CcSEcCtD
Aclidinium—Eye disorder—Docetaxel—breast cancer	0.00039	0.00173	CcSEcCtD
Aclidinium—Vomiting—Tamoxifen—breast cancer	0.000387	0.00172	CcSEcCtD
Aclidinium—Cardiac failure—Doxorubicin—breast cancer	0.000386	0.00171	CcSEcCtD
Aclidinium—Headache—Tamoxifen—breast cancer	0.000381	0.00169	CcSEcCtD
Aclidinium—Vomiting—Melphalan—breast cancer	0.000379	0.00168	CcSEcCtD
Aclidinium—Eye disorder—Capecitabine—breast cancer	0.000378	0.00168	CcSEcCtD
Aclidinium—Osteoarthritis—Doxorubicin—breast cancer	0.000377	0.00167	CcSEcCtD
Aclidinium—Mediastinal disorder—Docetaxel—breast cancer	0.000376	0.00167	CcSEcCtD
Aclidinium—Cough—Paclitaxel—breast cancer	0.000374	0.00166	CcSEcCtD
Aclidinium—BCHE—endocrine gland—breast cancer	0.000372	0.021	CbGeAlD
Aclidinium—Gastrointestinal disorder—Irinotecan—breast cancer	0.00037	0.00165	CcSEcCtD
Aclidinium—Vomiting—Goserelin—breast cancer	0.000369	0.00164	CcSEcCtD
Aclidinium—Mediastinal disorder—Capecitabine—breast cancer	0.000364	0.00162	CcSEcCtD
Aclidinium—Nasopharyngitis—Epirubicin—breast cancer	0.000364	0.00162	CcSEcCtD
Aclidinium—Headache—Goserelin—breast cancer	0.000364	0.00162	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Gemcitabine—breast cancer	0.000361	0.0016	CcSEcCtD
Aclidinium—Dry mouth—Paclitaxel—breast cancer	0.000357	0.00159	CcSEcCtD
Aclidinium—Diarrhoea—Vinorelbine—breast cancer	0.000356	0.00158	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Fluorouracil—breast cancer	0.000355	0.00158	CcSEcCtD
Aclidinium—Infection—Paclitaxel—breast cancer	0.000348	0.00154	CcSEcCtD
Aclidinium—Nervous system disorder—Paclitaxel—breast cancer	0.000343	0.00152	CcSEcCtD
Aclidinium—Tachycardia—Paclitaxel—breast cancer	0.000341	0.00152	CcSEcCtD
Aclidinium—Diarrhoea—Thiotepa—breast cancer	0.00034	0.00151	CcSEcCtD
Aclidinium—Nasopharyngitis—Doxorubicin—breast cancer	0.000337	0.0015	CcSEcCtD
Aclidinium—Infestation NOS—Methotrexate—breast cancer	0.000335	0.00149	CcSEcCtD
Aclidinium—Infestation—Methotrexate—breast cancer	0.000335	0.00149	CcSEcCtD
Aclidinium—Vision blurred—Capecitabine—breast cancer	0.000332	0.00147	CcSEcCtD
Aclidinium—Vomiting—Vinorelbine—breast cancer	0.000331	0.00147	CcSEcCtD
Aclidinium—Headache—Vinorelbine—breast cancer	0.000326	0.00145	CcSEcCtD
Aclidinium—Cough—Docetaxel—breast cancer	0.000317	0.00141	CcSEcCtD
Aclidinium—Vomiting—Thiotepa—breast cancer	0.000316	0.0014	CcSEcCtD
Aclidinium—Infestation NOS—Epirubicin—breast cancer	0.000314	0.00139	CcSEcCtD
Aclidinium—Infestation—Epirubicin—breast cancer	0.000314	0.00139	CcSEcCtD
Aclidinium—Headache—Thiotepa—breast cancer	0.000311	0.00138	CcSEcCtD
Aclidinium—Cough—Capecitabine—breast cancer	0.000307	0.00136	CcSEcCtD
Aclidinium—Dry mouth—Docetaxel—breast cancer	0.000303	0.00134	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Paclitaxel—breast cancer	0.000302	0.00134	CcSEcCtD
Aclidinium—Urinary tract disorder—Methotrexate—breast cancer	0.000297	0.00132	CcSEcCtD
Aclidinium—Urethral disorder—Methotrexate—breast cancer	0.000295	0.00131	CcSEcCtD
Aclidinium—Infection—Docetaxel—breast cancer	0.000295	0.00131	CcSEcCtD
Aclidinium—Sinusitis—Epirubicin—breast cancer	0.000294	0.00131	CcSEcCtD
Aclidinium—Diarrhoea—Mitoxantrone—breast cancer	0.000294	0.0013	CcSEcCtD
Aclidinium—Diarrhoea—Irinotecan—breast cancer	0.000294	0.0013	CcSEcCtD
Aclidinium—Dry mouth—Capecitabine—breast cancer	0.000293	0.0013	CcSEcCtD
Aclidinium—Nervous system disorder—Docetaxel—breast cancer	0.000291	0.00129	CcSEcCtD
Aclidinium—Infestation NOS—Doxorubicin—breast cancer	0.00029	0.00129	CcSEcCtD
Aclidinium—Infestation—Doxorubicin—breast cancer	0.00029	0.00129	CcSEcCtD
Aclidinium—Tachycardia—Docetaxel—breast cancer	0.000289	0.00129	CcSEcCtD
Aclidinium—Diarrhoea—Gemcitabine—breast cancer	0.000286	0.00127	CcSEcCtD
Aclidinium—Infection—Capecitabine—breast cancer	0.000285	0.00127	CcSEcCtD
Aclidinium—Rhinitis—Epirubicin—breast cancer	0.000282	0.00125	CcSEcCtD
Aclidinium—Nervous system disorder—Capecitabine—breast cancer	0.000282	0.00125	CcSEcCtD
Aclidinium—Eye disorder—Methotrexate—breast cancer	0.000281	0.00125	CcSEcCtD
Aclidinium—Diarrhoea—Fluorouracil—breast cancer	0.000281	0.00125	CcSEcCtD
Aclidinium—Tachycardia—Capecitabine—breast cancer	0.00028	0.00125	CcSEcCtD
Aclidinium—Urinary tract disorder—Epirubicin—breast cancer	0.000278	0.00124	CcSEcCtD
Aclidinium—Urethral disorder—Epirubicin—breast cancer	0.000276	0.00123	CcSEcCtD
Aclidinium—Vomiting—Mitoxantrone—breast cancer	0.000273	0.00121	CcSEcCtD
Aclidinium—Vomiting—Irinotecan—breast cancer	0.000273	0.00121	CcSEcCtD
Aclidinium—Sinusitis—Doxorubicin—breast cancer	0.000272	0.00121	CcSEcCtD
Aclidinium—Mediastinal disorder—Methotrexate—breast cancer	0.000271	0.00121	CcSEcCtD
Aclidinium—Headache—Irinotecan—breast cancer	0.000269	0.00119	CcSEcCtD
Aclidinium—Headache—Mitoxantrone—breast cancer	0.000269	0.00119	CcSEcCtD
Aclidinium—Vomiting—Gemcitabine—breast cancer	0.000266	0.00118	CcSEcCtD
Aclidinium—Eye disorder—Epirubicin—breast cancer	0.000263	0.00117	CcSEcCtD
Aclidinium—Headache—Gemcitabine—breast cancer	0.000262	0.00116	CcSEcCtD
Aclidinium—Vomiting—Fluorouracil—breast cancer	0.000261	0.00116	CcSEcCtD
Aclidinium—Rhinitis—Doxorubicin—breast cancer	0.000261	0.00116	CcSEcCtD
Aclidinium—Headache—Fluorouracil—breast cancer	0.000257	0.00114	CcSEcCtD
Aclidinium—Urinary tract disorder—Doxorubicin—breast cancer	0.000257	0.00114	CcSEcCtD
Aclidinium—BCHE—lymph node—breast cancer	0.000257	0.0145	CbGeAlD
Aclidinium—Gastrointestinal disorder—Docetaxel—breast cancer	0.000256	0.00114	CcSEcCtD
Aclidinium—Urethral disorder—Doxorubicin—breast cancer	0.000255	0.00113	CcSEcCtD
Aclidinium—Mediastinal disorder—Epirubicin—breast cancer	0.000254	0.00113	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Capecitabine—breast cancer	0.000248	0.0011	CcSEcCtD
Aclidinium—Vision blurred—Methotrexate—breast cancer	0.000247	0.0011	CcSEcCtD
Aclidinium—Eye disorder—Doxorubicin—breast cancer	0.000243	0.00108	CcSEcCtD
Aclidinium—Diarrhoea—Paclitaxel—breast cancer	0.000239	0.00106	CcSEcCtD
Aclidinium—Mediastinal disorder—Doxorubicin—breast cancer	0.000235	0.00104	CcSEcCtD
Aclidinium—Vision blurred—Epirubicin—breast cancer	0.000231	0.00103	CcSEcCtD
Aclidinium—Cough—Methotrexate—breast cancer	0.000229	0.00102	CcSEcCtD
Aclidinium—Vomiting—Paclitaxel—breast cancer	0.000222	0.000989	CcSEcCtD
Aclidinium—Headache—Paclitaxel—breast cancer	0.000219	0.000974	CcSEcCtD
Aclidinium—Cough—Epirubicin—breast cancer	0.000214	0.000951	CcSEcCtD
Aclidinium—Vision blurred—Doxorubicin—breast cancer	0.000214	0.00095	CcSEcCtD
Aclidinium—Infection—Methotrexate—breast cancer	0.000212	0.000944	CcSEcCtD
Aclidinium—Nervous system disorder—Methotrexate—breast cancer	0.00021	0.000932	CcSEcCtD
Aclidinium—Dry mouth—Epirubicin—breast cancer	0.000204	0.000907	CcSEcCtD
Aclidinium—Diarrhoea—Docetaxel—breast cancer	0.000203	0.000902	CcSEcCtD
Aclidinium—Infection—Epirubicin—breast cancer	0.000199	0.000883	CcSEcCtD
Aclidinium—Cough—Doxorubicin—breast cancer	0.000198	0.00088	CcSEcCtD
Aclidinium—Diarrhoea—Capecitabine—breast cancer	0.000196	0.000873	CcSEcCtD
Aclidinium—Nervous system disorder—Epirubicin—breast cancer	0.000196	0.000872	CcSEcCtD
Aclidinium—Tachycardia—Epirubicin—breast cancer	0.000195	0.000868	CcSEcCtD
Aclidinium—Dry mouth—Doxorubicin—breast cancer	0.000189	0.000839	CcSEcCtD
Aclidinium—Vomiting—Docetaxel—breast cancer	0.000189	0.000838	CcSEcCtD
Aclidinium—Headache—Docetaxel—breast cancer	0.000186	0.000826	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Methotrexate—breast cancer	0.000185	0.00082	CcSEcCtD
Aclidinium—Infection—Doxorubicin—breast cancer	0.000184	0.000817	CcSEcCtD
Aclidinium—Vomiting—Capecitabine—breast cancer	0.000183	0.000811	CcSEcCtD
Aclidinium—Nervous system disorder—Doxorubicin—breast cancer	0.000181	0.000807	CcSEcCtD
Aclidinium—Tachycardia—Doxorubicin—breast cancer	0.000181	0.000803	CcSEcCtD
Aclidinium—Headache—Capecitabine—breast cancer	0.00018	0.000799	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Epirubicin—breast cancer	0.000173	0.000768	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Doxorubicin—breast cancer	0.00016	0.00071	CcSEcCtD
Aclidinium—Diarrhoea—Methotrexate—breast cancer	0.000146	0.00065	CcSEcCtD
Aclidinium—Diarrhoea—Epirubicin—breast cancer	0.000137	0.000608	CcSEcCtD
Aclidinium—Vomiting—Methotrexate—breast cancer	0.000136	0.000604	CcSEcCtD
Aclidinium—Headache—Methotrexate—breast cancer	0.000134	0.000595	CcSEcCtD
Aclidinium—Vomiting—Epirubicin—breast cancer	0.000127	0.000565	CcSEcCtD
Aclidinium—Diarrhoea—Doxorubicin—breast cancer	0.000127	0.000563	CcSEcCtD
Aclidinium—Headache—Epirubicin—breast cancer	0.000125	0.000557	CcSEcCtD
Aclidinium—Vomiting—Doxorubicin—breast cancer	0.000118	0.000523	CcSEcCtD
Aclidinium—Headache—Doxorubicin—breast cancer	0.000116	0.000515	CcSEcCtD
Aclidinium—CHRM4—Signaling Pathways—ERBB2—breast cancer	1.01e-05	8.75e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—FGFR1—breast cancer	1.01e-05	8.73e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—FGFR1—breast cancer	1e-05	8.65e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—MTOR—breast cancer	1e-05	8.64e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—PIK3CB—breast cancer	1e-05	8.64e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—HIF1A—breast cancer	9.99e-06	8.63e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—HIF1A—breast cancer	9.96e-06	8.6e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—PIK3CA—breast cancer	9.89e-06	8.53e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—HIF1A—breast cancer	9.86e-06	8.52e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—MDM2—breast cancer	9.85e-06	8.5e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—RAF1—breast cancer	9.81e-06	8.47e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—RELA—breast cancer	9.77e-06	8.43e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—LEP—breast cancer	9.75e-06	8.42e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—LEP—breast cancer	9.72e-06	8.39e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—ERBB2—breast cancer	9.71e-06	8.38e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CAV1—breast cancer	9.66e-06	8.34e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CAV1—breast cancer	9.63e-06	8.32e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—LEP—breast cancer	9.63e-06	8.31e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CXCL8—breast cancer	9.61e-06	8.3e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—PIK3CB—breast cancer	9.58e-06	8.27e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—MTOR—breast cancer	9.58e-06	8.27e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—KDR—breast cancer	9.56e-06	8.25e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—HRAS—breast cancer	9.55e-06	8.25e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CAV1—breast cancer	9.54e-06	8.24e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—KDR—breast cancer	9.53e-06	8.22e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—KDR—breast cancer	9.43e-06	8.14e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CDKN1B—breast cancer	9.39e-06	8.1e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—ESR1—breast cancer	9.31e-06	8.04e-05	CbGpPWpGaD
Aclidinium—CHRM4—GPCR downstream signaling—AKT1—breast cancer	9.29e-06	8.02e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—ESR1—breast cancer	9.28e-06	8.01e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PIK3CD—breast cancer	9.23e-06	7.96e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CXCL8—breast cancer	9.21e-06	7.95e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CASP3—breast cancer	9.2e-06	7.94e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—FN1—breast cancer	9.2e-06	7.94e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—ESR1—breast cancer	9.19e-06	7.94e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—IL2—breast cancer	9.19e-06	7.93e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—FN1—breast cancer	9.17e-06	7.92e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—HRAS—breast cancer	9.15e-06	7.9e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—IL6—breast cancer	9.14e-06	7.89e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—ALB—breast cancer	9.11e-06	7.86e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—NFKBIA—breast cancer	9.09e-06	7.85e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—FN1—breast cancer	9.08e-06	7.84e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—NFKBIA—breast cancer	9.06e-06	7.82e-05	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—PTEN—breast cancer	9.04e-06	7.8e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—NOTCH1—breast cancer	9e-06	7.77e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CDKN1B—breast cancer	8.99e-06	7.76e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—NOTCH1—breast cancer	8.97e-06	7.75e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—NFKBIA—breast cancer	8.97e-06	7.75e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CCND1—breast cancer	8.96e-06	7.73e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—JUN—breast cancer	8.94e-06	7.72e-05	CbGpPWpGaD
Aclidinium—CHRM5—GPCR downstream signaling—AKT1—breast cancer	8.89e-06	7.68e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—NOTCH1—breast cancer	8.89e-06	7.67e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CTNNB1—breast cancer	8.87e-06	7.66e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CASP3—breast cancer	8.81e-06	7.61e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—APC—breast cancer	8.8e-06	7.6e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PIK3CG—breast cancer	8.8e-06	7.6e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—KIT—breast cancer	8.8e-06	7.6e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—IL2—breast cancer	8.8e-06	7.6e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—KIT—breast cancer	8.77e-06	7.58e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—APC—breast cancer	8.77e-06	7.58e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PIK3CG—breast cancer	8.77e-06	7.58e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—IL6—breast cancer	8.75e-06	7.56e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—NOS3—breast cancer	8.71e-06	7.52e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—EGF—breast cancer	8.7e-06	7.51e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—MMP9—breast cancer	8.69e-06	7.51e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—KIT—breast cancer	8.69e-06	7.5e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PIK3CG—breast cancer	8.69e-06	7.5e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—APC—breast cancer	8.69e-06	7.5e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—EGF—breast cancer	8.67e-06	7.49e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CDKN1A—breast cancer	8.66e-06	7.48e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—PTEN—breast cancer	8.64e-06	7.46e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—EGF—breast cancer	8.59e-06	7.42e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CCND1—breast cancer	8.58e-06	7.4e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—JUN—breast cancer	8.56e-06	7.39e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CTNNB1—breast cancer	8.49e-06	7.33e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—MAPK8—breast cancer	8.46e-06	7.3e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—AKT1—breast cancer	8.43e-06	7.28e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—MAPK3—breast cancer	8.43e-06	7.28e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—MAPK3—breast cancer	8.4e-06	7.26e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—MMP9—breast cancer	8.33e-06	7.19e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—MAPK3—breast cancer	8.32e-06	7.18e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CDKN1A—breast cancer	8.3e-06	7.16e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—PTEN—breast cancer	8.28e-06	7.15e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—BRAF—breast cancer	8.27e-06	7.14e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—BRAF—breast cancer	8.25e-06	7.12e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—BRAF—breast cancer	8.17e-06	7.05e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—MAPK8—breast cancer	8.1e-06	6.99e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—AKT1—breast cancer	8.08e-06	6.97e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—IGF1—breast cancer	8.06e-06	6.96e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—AKT2—breast cancer	8.05e-06	6.95e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PIK3CB—breast cancer	8.04e-06	6.94e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—IGF1—breast cancer	8.03e-06	6.94e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—AKT2—breast cancer	8.03e-06	6.93e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—EGFR—breast cancer	8.02e-06	6.92e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—SRC—breast cancer	8.02e-06	6.92e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—EGFR—breast cancer	7.99e-06	6.9e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PTGS2—breast cancer	7.97e-06	6.88e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—IGF1—breast cancer	7.96e-06	6.87e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—AKT2—breast cancer	7.95e-06	6.86e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—EGFR—breast cancer	7.92e-06	6.83e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—VEGFA—breast cancer	7.81e-06	6.74e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PIK3CD—breast cancer	7.74e-06	6.68e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—STAT3—breast cancer	7.73e-06	6.67e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PIK3CD—breast cancer	7.71e-06	6.66e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—SRC—breast cancer	7.68e-06	6.63e-05	CbGpPWpGaD
Aclidinium—CHRM1—GPCR downstream signaling—PIK3CA—breast cancer	7.67e-06	6.62e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—SERPINE1—breast cancer	7.65e-06	6.61e-05	CbGpPWpGaD
Aclidinium—CHRM3—GPCR downstream signaling—PIK3CA—breast cancer	7.64e-06	6.6e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PIK3CD—breast cancer	7.64e-06	6.6e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—SERPINE1—breast cancer	7.63e-06	6.59e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—KRAS—breast cancer	7.58e-06	6.54e-05	CbGpPWpGaD
Aclidinium—CHRM2—GPCR downstream signaling—PIK3CA—breast cancer	7.57e-06	6.53e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—SERPINE1—breast cancer	7.56e-06	6.52e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—KRAS—breast cancer	7.55e-06	6.52e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—KRAS—breast cancer	7.48e-06	6.46e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—VEGFA—breast cancer	7.48e-06	6.46e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—STAT3—breast cancer	7.4e-06	6.39e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—MAPK3—breast cancer	7.39e-06	6.38e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—NOS3—breast cancer	7.31e-06	6.31e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—NOS3—breast cancer	7.28e-06	6.29e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—NOS3—breast cancer	7.21e-06	6.23e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—MYC—breast cancer	7.18e-06	6.2e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—TGFB1—breast cancer	7.17e-06	6.19e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—MAPK3—breast cancer	7.07e-06	6.11e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—EGFR—breast cancer	7.03e-06	6.07e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—PIK3CA—breast cancer	6.96e-06	6.01e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PTEN—breast cancer	6.95e-06	6e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—PIK3CA—breast cancer	6.94e-06	5.99e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MDM2—breast cancer	6.93e-06	5.99e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MDM2—breast cancer	6.91e-06	5.97e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—RAF1—breast cancer	6.91e-06	5.96e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—RAF1—breast cancer	6.89e-06	5.95e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—MYC—breast cancer	6.88e-06	5.94e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—RELA—breast cancer	6.88e-06	5.94e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—PIK3CA—breast cancer	6.87e-06	5.93e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—TGFB1—breast cancer	6.86e-06	5.92e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—RELA—breast cancer	6.86e-06	5.92e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MDM2—breast cancer	6.84e-06	5.91e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—ERBB2—breast cancer	6.84e-06	5.9e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—RAF1—breast cancer	6.82e-06	5.89e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—ERBB2—breast cancer	6.81e-06	5.88e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—RELA—breast cancer	6.79e-06	5.86e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—ERBB2—breast cancer	6.75e-06	5.83e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MTOR—breast cancer	6.75e-06	5.82e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PIK3CB—breast cancer	6.75e-06	5.82e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—EGFR—breast cancer	6.73e-06	5.81e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MTOR—breast cancer	6.72e-06	5.8e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PIK3CB—breast cancer	6.72e-06	5.8e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PIK3CB—breast cancer	6.66e-06	5.75e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MTOR—breast cancer	6.66e-06	5.75e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—KRAS—breast cancer	6.64e-06	5.73e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CXCL8—breast cancer	6.48e-06	5.6e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CXCL8—breast cancer	6.46e-06	5.58e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—HRAS—breast cancer	6.44e-06	5.56e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—HRAS—breast cancer	6.42e-06	5.54e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CXCL8—breast cancer	6.4e-06	5.52e-05	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—PIK3CA—breast cancer	6.37e-06	5.5e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—HRAS—breast cancer	6.36e-06	5.49e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—KRAS—breast cancer	6.36e-06	5.49e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CDKN1B—breast cancer	6.33e-06	5.46e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CDKN1B—breast cancer	6.31e-06	5.45e-05	CbGpPWpGaD
Aclidinium—CHRM1—GPCR downstream signaling—AKT1—breast cancer	6.26e-06	5.41e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CDKN1B—breast cancer	6.25e-06	5.39e-05	CbGpPWpGaD
Aclidinium—CHRM3—GPCR downstream signaling—AKT1—breast cancer	6.24e-06	5.39e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CASP3—breast cancer	6.2e-06	5.36e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—IL2—breast cancer	6.19e-06	5.35e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CASP3—breast cancer	6.18e-06	5.34e-05	CbGpPWpGaD
Aclidinium—CHRM2—GPCR downstream signaling—AKT1—breast cancer	6.18e-06	5.34e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—IL2—breast cancer	6.17e-06	5.33e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—IL6—breast cancer	6.16e-06	5.32e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—IL6—breast cancer	6.14e-06	5.3e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CASP3—breast cancer	6.12e-06	5.29e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—IL2—breast cancer	6.11e-06	5.28e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—PIK3CA—breast cancer	6.1e-06	5.26e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—IL6—breast cancer	6.08e-06	5.25e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CCND1—breast cancer	6.04e-06	5.21e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—JUN—breast cancer	6.03e-06	5.2e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CCND1—breast cancer	6.02e-06	5.2e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—JUN—breast cancer	6.01e-06	5.19e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CTNNB1—breast cancer	5.98e-06	5.16e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CCND1—breast cancer	5.96e-06	5.15e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CTNNB1—breast cancer	5.96e-06	5.15e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—JUN—breast cancer	5.95e-06	5.14e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CTNNB1—breast cancer	5.9e-06	5.1e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—TP53—breast cancer	5.9e-06	5.09e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MMP9—breast cancer	5.86e-06	5.06e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MMP9—breast cancer	5.84e-06	5.05e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CDKN1A—breast cancer	5.84e-06	5.04e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—PIK3CA—breast cancer	5.84e-06	5.04e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PTEN—breast cancer	5.83e-06	5.03e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CDKN1A—breast cancer	5.82e-06	5.03e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PTEN—breast cancer	5.81e-06	5.02e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MMP9—breast cancer	5.79e-06	5e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CDKN1A—breast cancer	5.77e-06	4.98e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PTEN—breast cancer	5.75e-06	4.97e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MAPK8—breast cancer	5.7e-06	4.92e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—AKT1—breast cancer	5.69e-06	4.91e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MAPK8—breast cancer	5.68e-06	4.91e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—AKT1—breast cancer	5.67e-06	4.89e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—TP53—breast cancer	5.65e-06	4.88e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—HRAS—breast cancer	5.64e-06	4.87e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MAPK8—breast cancer	5.63e-06	4.86e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—AKT1—breast cancer	5.61e-06	4.85e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—SRC—breast cancer	5.41e-06	4.67e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—HRAS—breast cancer	5.4e-06	4.66e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—IL6—breast cancer	5.4e-06	4.66e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—SRC—breast cancer	5.39e-06	4.65e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—SRC—breast cancer	5.34e-06	4.61e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—VEGFA—breast cancer	5.26e-06	4.55e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—VEGFA—breast cancer	5.25e-06	4.53e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—STAT3—breast cancer	5.21e-06	4.5e-05	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—AKT1—breast cancer	5.21e-06	4.5e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—VEGFA—breast cancer	5.2e-06	4.49e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—STAT3—breast cancer	5.2e-06	4.49e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—IL6—breast cancer	5.17e-06	4.46e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—STAT3—breast cancer	5.15e-06	4.44e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—AKT1—breast cancer	4.98e-06	4.3e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MAPK3—breast cancer	4.98e-06	4.3e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MAPK3—breast cancer	4.96e-06	4.29e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MAPK3—breast cancer	4.92e-06	4.24e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PIK3CA—breast cancer	4.9e-06	4.23e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MYC—breast cancer	4.84e-06	4.18e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—TGFB1—breast cancer	4.83e-06	4.17e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MYC—breast cancer	4.83e-06	4.17e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—TGFB1—breast cancer	4.82e-06	4.16e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MYC—breast cancer	4.78e-06	4.13e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—AKT1—breast cancer	4.77e-06	4.12e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—TGFB1—breast cancer	4.77e-06	4.12e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—EGFR—breast cancer	4.74e-06	4.09e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—EGFR—breast cancer	4.72e-06	4.08e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—EGFR—breast cancer	4.68e-06	4.04e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—KRAS—breast cancer	4.48e-06	3.86e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—KRAS—breast cancer	4.46e-06	3.85e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—KRAS—breast cancer	4.42e-06	3.81e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PIK3CA—breast cancer	4.11e-06	3.55e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PIK3CA—breast cancer	4.1e-06	3.54e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PIK3CA—breast cancer	4.06e-06	3.5e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—AKT1—breast cancer	4e-06	3.46e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—TP53—breast cancer	3.98e-06	3.43e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—TP53—breast cancer	3.97e-06	3.42e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—TP53—breast cancer	3.93e-06	3.39e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—HRAS—breast cancer	3.8e-06	3.28e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—HRAS—breast cancer	3.79e-06	3.27e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—HRAS—breast cancer	3.76e-06	3.24e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—IL6—breast cancer	3.64e-06	3.14e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—IL6—breast cancer	3.63e-06	3.13e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—IL6—breast cancer	3.59e-06	3.1e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—AKT1—breast cancer	3.36e-06	2.9e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—AKT1—breast cancer	3.35e-06	2.89e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—AKT1—breast cancer	3.32e-06	2.86e-05	CbGpPWpGaD
